Arrowhead reports FY2026 results, highlights REDEMPLO growth and sNDA submissionNov 12Quarterly updateArrowhead Pharmaceuticalsplozasiran
Arrowhead refinances $400 million Sixth Street facility at lower rateNov 4FinancingArrowhead Pharmaceuticals
Arrowhead's two Phase 3 plozasiran SHTG trials both show completed status this weekOct 9Weekly roundup, 4 itemsARO-INHBEArrowhead PharmaceuticalsUpdated
Arrowhead's SHASTA-10 extension study for plozasiran stays active, not recruitingOct 1Trial updateArrowhead Pharmaceuticalsplozasiran
Arrowhead reports fiscal Q3 2026 results with plozasiran Phase 3 data and Madrigal dealAug 4Quarterly updateArrowhead Pharmaceuticalsplozasiran